Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721577 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
A Phase 1 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01721577 is a Phase 1 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT01721577, a Phase 1 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in patients with recurrent malignant astrocytomas (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma). Patients will be treated for up to 5 cycles. A treatment cycle is defined as 28 days+7 days rest (28+7 days during cycle 1 to 4, and 28 days during cycle 5). The following cycle will not be started until the treatment continuation criteria are fulfilled. Concomitant supportive therapies will be allowed.
Interventions
- DRUG AXL1717
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721577
The ClinicalTrials.gov registry entry for NCT01721577 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AXL1717 is the first listed.
NCT01721577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721577 about?
NCT01721577 is a clinical study titled "Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas". This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in patients with recurrent malignant astrocytomas (glioblastoma, gliosarcoma, ana...
What is the current status of trial NCT01721577?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01721577?
The interventions under investigation include: AXL1717 (DRUG).
Who is sponsoring clinical trial NCT01721577?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.